Sprouts Farmers Market closes $600 million revolving credit facility
On Wednesday, JMP analysts, led by Jason Butler, maintained their positive outlook on Acadia Pharmaceuticals (NASDAQ:ACAD), reiterating a Market Outperform rating and a price target of $37.00. Currently trading at $17.20, the stock shows potential upside according to InvestingPro analysis, with analyst targets ranging from $11 to $37. The reaffirmation follows Acadia’s strong first-quarter performance in 2025, which surpassed both JMP’s and the consensus estimates for revenue and earnings.
Acadia Pharmaceuticals reported its financial results for the first quarter of 2025, marking the company’s sixth consecutive profitable quarter. With a robust gross profit margin of nearly 60% and revenue growth of 22.4% over the last twelve months, the results exceeded expectations, prompting the analysts at JMP to maintain their optimistic stance on the stock. Acadia also confirmed its sales guidance for the year, which includes expected ranges for its drugs NUPLAZID and DAYBUE.
The analysts highlighted NUPLAZID’s continued success and the robust patient growth for DAYBUE as key factors driving the company’s performance. They believe that DAYBUE’s commercial dynamics will support its growth trajectory both in the near term and looking further ahead.
In addition to the strong quarterly results, Acadia Pharmaceuticals is anticipated to generate over $100 million in cash in 2025. The company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 2.88. InvestingPro analysis reveals 8 additional key insights about Acadia’s financial health, available to subscribers. JMP analysts have made incremental updates to their model while maintaining their estimates for the company’s performance in the upcoming year.
Furthermore, there has been a positive development in Acadia’s clinical pipeline. The Phase 3 trial for ACP-101 in treating Prader-Willi Syndrome is progressing ahead of expectations. The trial results, which were initially expected in the first half of 2026, are now anticipated to be released in the fourth quarter of 2025. This advancement could potentially contribute to the company’s growth and the analysts’ positive projection for Acadia’s stock. For deeper insights into Acadia’s valuation and growth prospects, access the comprehensive Pro Research Report available exclusively on InvestingPro.
In other recent news, Acadia Pharmaceuticals has reported a strong start to 2025, with its first-quarter earnings exceeding expectations. The company posted earnings per share of $0.11, outperforming the anticipated loss of $0.02, and revenue reached $244.3 million, surpassing the forecast of $239.55 million. Acadia confirmed its full-year revenue outlook for its two marketed products, despite a slight shortfall in top-line revenue for Daybue. Notably, Nuplazid sales hit $159.7 million, marking a 23% year-over-year growth. Stifel analysts maintained a Hold rating on Acadia, with a price target of $18.00, acknowledging the company’s generally strong earnings. They also highlighted the accelerated timeline for phase 3 data on ACP-101 for Prader-Willi syndrome, now expected in early fourth quarter of 2025. This development is attributed to faster-than-expected patient enrollment, although analysts noted the market’s underappreciation of this aspect of Acadia’s pipeline. The company is also preparing for potential regulatory submissions for Prader-Willi syndrome in the first quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.